Review Spotlights Senotherapeutics as Emerging Approach for Metabolic Disease

Overview

• Published November 5 in the Journal of Internal Medicine, the peer‑reviewed review is titled “Senotherapeutics for Metabolic Disease and Diabetic Complications” (DOI: 10.1111/joim.70039).
• The authors synthesize evidence that cellular senescence contributes to obesity, type 2 diabetes, and metabolic syndrome by impairing tissue function.
• Senescent cells accumulate in metabolic tissues and secrete factors that drive chronic inflammation and fibrosis.
• The paper outlines three intervention classes: senolytics that eliminate senescent cells, senomorphics that suppress their secretions, and senosensitizers that make them easier to clear.
• Corresponding author Allyson Palmer of the Mayo Clinic describes senotherapeutics as an emerging class that could transform treatment and prevention by targeting a root driver of disease.